Close menu




December 17th, 2025 | 07:35 CET

Winners for 2026: RZOLV Technologies, Evotec, Mutares have what it takes – which developments are crucial?

  • Technology
  • cleantech
  • Biotechnology
Photo credits: pixabay.com

The 2025 stock market year was full of exciting developments. Bull markets in commodities, interest rate cuts, and geopolitical tensions. However, some companies, such as Evotec, had to deal with many home-grown problems and lagged behind the positive performance of the overall market. Mutares saw its coffers fill up, but its share price could have done better this year. Next year could be very successful for RZOLV Technologies. The Canadians are solving a major problem in gold mining.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: RZOLV TECHNOLOGIES INC | CA76091C1032 , EVOTEC SE INH O.N. | DE0005664809 , MUTARES KGAA NA O.N. | DE000A2NB650

Table of contents:


    RZOLV Technologies – Innovative solution with great potential

    The price of gold is at a record high, and gold miners are working flat out. RZOLV Technologies is solving a major problem associated with the negative effects of gold mining and could soon tap into a large market or become a takeover candidate.

    For years, the Canadian company has been researching a safe alternative to sodium cyanide. This toxic chemical is used almost everywhere in the world to efficiently leach finely distributed gold from low-grade ores. However, resistance to the use of sodium cyanide is growing. The global cyanide market has an annual volume of around USD 2.4 billion.

    The Canadians hope to capture a 10% share of this market. RZOLV has developed a water-based, non-toxic leaching formulation and has applied for a patent for the process. The results of independent testing by SGS and other external tests have impressively confirmed that RZOLV's approach is on par with previous methods in terms of yield and speed. A major advantage in practical application for mining companies is that RZOLV's solution can be easily integrated into existing production.

    However, it can be used not only for gold extraction, but also for the extraction of critical metals and rare earths. This significantly increases the market potential. The Canadian solution is compatible with common processing technologies and is energy-efficient even at room temperature.

    On the way to industrial scale, a 100-ton pilot test is currently planned in Arizona. If the results are positive, the innovative Canadian solution will go into mass production or be licensed out. Given the disruptive potential of the approach and a market capitalization of only CAD 29 million, the Company could soon become a takeover candidate.

    Evotec – Potential takeover candidate

    According to current data, M&A volume in the first quarter of the year was high at USD 37.7 billion. Although several larger deals took place, around 90% of the transactions were worth less than USD 1 billion each. The larger transactions mostly involved strategic additions to pipelines. The strategic logic behind the "smaller" deals was to expand innovation pipelines and gain access to new therapeutic areas. When will Evotec appear in these statistics?

    The shares of the Hamburg-based drug discovery and development specialist plummeted last year as a result of strategic and operational problems and are currently bottoming out in the EUR 5 range. Somewhat surprisingly, the investment holding company of the Danish pharmaceutical group Novo Nordisk recently sold a large block of shares at the low price level.

    Evotec's business activities include extensive and broad-based partnership models with the top 20 pharmaceutical companies, several hundred biotech companies, and academic institutions. The Company's strategic market position and low valuation of EUR 900 million make it a potential takeover candidate. Analysts have set an average price target of EUR 8.50, representing upside potential of around 65%.

    Mutares – Specialist in corporate investments

    The private equity holding company generates its profits by buying and selling corporate stakes. Based in Munich, Mutares acquires companies undergoing transitional phases that show significant operational improvement potential and sells them again after stabilization and repositioning. The success of this strategy and the high returns it has generated can be seen impressively in the Steyr investment.

    Mutares acquired the Austrian defense specialist in 2022, brought it to market in 2024, and cashed in on the investment this year with a gross return of an impressive EUR 170 million. This compares with a current market capitalization of just over EUR 600 million. Analysts assign the stock upside potential of over 50%, in addition to a generous dividend yield of around 7%.


    RZOLV solves a major problem in gold mining by eliminating the use of toxic chemicals in the leaching process. Following a successful pilot phase, the Company plans to enter the mass market. A market-ready solution could also attract attention and make the Company a potential takeover target. Evotec and Mutares are positively rated by analysts and show significant upside potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Jens Castner on October 28th, 2026 | 05:40 CET

    The Art of the Turnaround: Microsoft, Power Metallic Mines, innoscripta and CTS Eventim Prepare for a Comeback

    • Technology
    • Critical raw materials
    • Software
    • Strategic metals
    • Quarterly results
    • Copper
    • Tax evasion
    • Raid
    • Analysts
    • Mag-7
    • Microsoft
    • Power Metallic Mines
    • innoscripta

    Created and published on behalf of Power Metallic Mines

    Microsoft showed what a turnaround looks like in the summer. After a weak first half, strong annual results gave the shares a substantial boost. Tonight, the software giant must prove that the recovery is sustainable. Two other stocks could now be on the verge of a similar turnaround. At Power Metallic Mines, a copper price near its record high and a high-grade deposit meet a share price that analysts consider significantly undervalued. Their price targets are around three times the current level. Meanwhile, German growth company innoscripta plunged by more than half following a raid but is already showing signs of recovery. CTS Eventim, the MDAX-listed ticketing company, has also moved beyond its recent lows. Both its CEO and an activist investor consider the stock severely undervalued.

    Read

    Commented by Stefan Feulner on October 22nd, 2026 | 05:25 CEST

    BioNTech, Formycon, Biogen: Pharma billions are being redistributed

    • Biotechnology

    The pharmaceutical industry is facing a massive restructuring. As blockbuster drugs worth billions lose patent exclusivity, cheaper copycat products are entering the market. At the same time, biotech groups are investing billions in new cancer drugs and therapies for diseases that have long been difficult to treat. For investors, this creates tension between established revenue generators, new active ingredients and rising healthcare costs. Companies that secure access to lucrative drug markets early are particularly interesting. Even a small share of a global blockbuster's revenue can have considerable economic significance.

    Read

    Commented by Stefan Feulner on October 21st, 2026 | 05:38 CEST

    Regeneron, Vidac Pharma, Krystal Biotech: New Active Ingredients, Enormous Stock Market Potential

    • Biotechnology

    Cancer treatment is undergoing a fundamental transformation. Rather than relying solely on conventional chemotherapy, new approaches increasingly target the biological mechanisms that drive tumours. In particular, immunotherapies, gene therapies and interventions targeting cellular metabolism are opening up new possibilities for treating skin cancer. As approved medicines reach more patients, innovative biotech companies face key clinical milestones. Commercial opportunities are substantial, as demand for effective, well-tolerated treatments continues to grow. The decisive factor will be which technologies can confirm their promising results in larger clinical trials.

    Read